Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis

Zhengzhou University

Status: Unknown

Conditions: Clinical Pregnancy Rate

Treatments: Drug: Long term GnRH-a (3.75mg)

Study type: Interventional

Funder types: Other

Identifiers

NCT03006406

ENDO-1

Details and patient eligibility

About

Gonadotropin-releasing hormone analogue (GnRH-a) is a synthetic decapeptide compound which can down-regulate pituitary function causing a temporary low estrogen state. Since endometriosis is an estrogen-dependent disease, the use of long-acting GnRH-a can control the growth of endometriosis by inhibiting ovary function.Some scholars have found that, for adenomyosis patients who received a super long protocol (pretreatment of long-acting GnRH-a for 1-2 months) in IVF treatment, the pregnancy outcome is comparable to that of the controls with normal uterus. Thus, the aim of this study is to compare the clinical pregnancy rate in patients treated with GnRH-a for 1, or 2 months.

Enrollment: 50 estimated patients

Sex: Female

Ages: 22 to 42 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• first IVF cycle;
• with normal ovarian reserve(FSH(10miu/ml； antral follicle count )3)
• with normal uterine

Exclusion criteria

• Pre-implantation genetic diagnosis cycles;
• Oocyte donation cycles

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups

Long term GnRH-a for 1 month

Active Comparator group

Description:

patient in this group only receive GnRH-a 3.75 for 1 month

Treatment:

Drug: Long term GnRH-a (3.75mg)

patient in this group only receive GnRH-a 3.75 for 2 month

Experimental group

Description:

patient in this group only receive GnRH-a 3.75 for 2 month

Treatment:

Drug: Long term GnRH-a (3.75mg)